Patents Assigned to Ariagen, Inc.
  • Patent number: 11459322
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: October 4, 2022
    Assignee: ARIAGEN, INC.
    Inventors: Peter Colabuono, Graham Johnson, David Douglas Manning, Mark Allan Wolf
  • Patent number: 11427576
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: August 30, 2022
    Assignee: ARIAGEN, INC.
    Inventors: Peter Colabuono, Graham Johnson, David Douglas Manning, Mark Allan Wolf
  • Patent number: 11390621
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: July 19, 2022
    Assignee: ARIAGEN, INC.
    Inventors: Graham Johnson, Peter Colabuono, Paul Gerard Pearson, David Douglas Manning
  • Publication number: 20210347794
    Abstract: The present disclosure relates to phosphate derivatives of indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients such as cancer patients.
    Type: Application
    Filed: September 23, 2019
    Publication date: November 11, 2021
    Applicant: ARIAGEN, INC.
    Inventors: Graham Johnson, David Douglas Manning
  • Publication number: 20210188834
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 24, 2021
    Applicant: ARIAGEN, INC.
    Inventors: Graham Johnson, Peter Colabuono, Paul Gerard Pearson, David Douglas Manning
  • Publication number: 20210179604
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 17, 2021
    Applicant: ARIAGEN, INC.
    Inventors: Peter Colabuono, Graham Johnson, David Douglas Manning, Mark Allan Wolf
  • Publication number: 20200354353
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Application
    Filed: November 19, 2018
    Publication date: November 12, 2020
    Applicant: ARIAGEN, INC.
    Inventors: Peter Colabuono, Graham Johnson, David Douglas Manning, Mark Allan Wolf
  • Publication number: 20200323827
    Abstract: A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 15, 2020
    Applicant: Ariagen, Inc.
    Inventor: Jiasheng Song
  • Patent number: 10632106
    Abstract: Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: April 28, 2020
    Assignee: Ariagen, Inc.
    Inventor: Jiasheng Song
  • Publication number: 20190307731
    Abstract: Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, two Ra are independently H or two Ra together form ?O or ?N—W3—R1; A is a C6 to C10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C2-C10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, O, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C?N and interrupted by 1 to 3 heteroatoms selected from N, O, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, O, and S; and R is Rc which is C-attached or RN which is N-attached.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 10, 2019
    Applicant: Ariagen, Inc.
    Inventors: Luqing YANG, Guodong LI, Suoming ZHANG
  • Publication number: 20190284149
    Abstract: Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n?1, CnH2n?3, two Ra are independently H or two Ra together form =0 or ?N—W3—R1; A is a C6 to C10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C2-C10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, 0, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C?N and interrupted by 1 to 3 heteroatoms selected from N, 0, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, 0, and S; and R is RC which is C-attached or RN which is N-attached.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 19, 2019
    Applicant: ARIAGEN, INC.
    Inventors: Jiasheng Song, Suoming Zhang, Guodong Li, Luqing Yang
  • Publication number: 20190275011
    Abstract: A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.
    Type: Application
    Filed: December 5, 2018
    Publication date: September 12, 2019
    Applicant: Ariagen, Inc.
    Inventor: Jiasheng Song
  • Publication number: 20190134009
    Abstract: Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.
    Type: Application
    Filed: July 27, 2018
    Publication date: May 9, 2019
    Applicant: Ariagen, Inc.
    Inventor: Jiasheng Song
  • Publication number: 20190084948
    Abstract: Methods of synthesizing 2?(1?H-indole-3?-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and structural analogs thereof. The methods include condensation reactions or condensation and oxidation reactions to form the thiazoline or thiazole moiety of ITE or its structural analogs.
    Type: Application
    Filed: August 16, 2018
    Publication date: March 21, 2019
    Applicant: Ariagen, Inc.
    Inventors: Jiasheng Song, Suoming Zhang, Guodong Li, Luqing Yang
  • Patent number: 10195182
    Abstract: A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 5, 2019
    Assignee: Ariagen, Inc.
    Inventor: Jiasheng Song
  • Patent number: 10081610
    Abstract: Methods of synthesizing 2-(1?H-indole-3?-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and structural analogs thereof. The methods include condensation reactions or condensation and oxidation reactions to form the thiazoline or thiazole moiety of ITE or its structural analogs.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: September 25, 2018
    Assignee: ARIAGEN, INC.
    Inventors: Jiasheng Song, Suoming Zhang, Guodong Li, Luquing Yang
  • Publication number: 20170333401
    Abstract: A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.
    Type: Application
    Filed: June 5, 2017
    Publication date: November 23, 2017
    Applicant: Ariagen, Inc.
    Inventor: Jiasheng Song